STALICLA
STALICLA has developed the first neurodevelopmental disorder-specific precision medicine discovery platform with an initial application in autism spectrum disorder (ASD). Until now, patient diagnosis and drug development for ASD and other NDDs have relied on behaviorally based disease classifications, which do not correlate with biological status and fail to acknowledge patient diversity-contributing to high rates of clinical failure. STALICLA’s DEPI technology is looking to change that by integrating clinical, genetic and molecular data to identify biologically distinct subgroups and treatments to match.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Clinical Services
- Market Focus:
- Internationally (various countries)
About Us
Breaking through one-size-fits-all diagnostics
Just as the lived experiences of people diagnosed with neurodevelopmental disorders (NDDs) are unique, many NDDs that currently fall under the same disease category have very different biological bases.
At STALICLA, we want to recognize and put that heterogeneity to work—leveraging biomedical and clinical data to gain new insights into biologically distinct patient populations and treatments to match.
We’ve developed first-in-class systems biology and AI technology that harnesses patients’ biological signatures along with complex data analysis to identify tailored treatment options that result in measurable clinical improvements.
Technology that speaks to biological complexity
Until now, patient diagnosis and drug development for ASD and other NDDs have relied on behaviorally based disease classifications, which do not correlate with biological status and fail to acknowledge patient diversity-contributing to high rates of clinical failure.
Team
STALICLA’s team is about science, experience and determination
Founded in 2017, STALICLA is a clinical-stage biopharmaceutical company with a team of domain experts, drug developers, clinicians, data scientists and computational biologists working to create NDD precision medicine solutions. 26 employees coming from world leading academic and large pharmaceutical centers (UCLA Geshwind Lab, BCN Super Computing Center, Max Planck Institute, ...) and large Pharmaceutical (Novartis, Roche, Takeda, Lundbeck, ...).
STALICLA operates across two units: the Drug Development Unit (DDU) located at STALICLA’s Geneva, Switzerland headquarters, and the Discovery and Data Science (DDS) unit with offices in Barcelona, Spain.
Our Experience
26 employees
coming from world leading academic and pharmaceutical centers
>80 domain
specific publications
>35 IND - CTA
4 Phase 3 (US, EU, Asia)
2 investigation
new drug application